Market sentiment around drug stock price shifts is heavily affected by regulatory approvals. Eli Lilly (LLY) hit $891.20 after positive Alzheimer’s trial data, positioning it for further momentum if Medicare coverage expands. Sector momentum suggests biotech ETFs may outperform in the next quarter. The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald Trump's intention to lower drug prices and slap a tariff on pharma imports. These two efforts could weigh significantly on these companies' earnings -- and uncertainty about when and how they would be rolled out prompted investors to think twice about buying shares of drugmakers. A value stock is usually one that has low classic value fundamentals such as a low price-to-earnings (P/E) or price-to-sales (P/S) ratio. It can also be a company that is out of favor with Wall Street or is lagging its peers. Drug stock price in mid-cap biotechs is supported by strong insider buying. Alnylam Pharmaceuticals (ALNY) rose to $189.20 after directors purchased sizable share blocks.